ProCE Banner Activity

Arlocabtagene Autoleucel, a GPRC5D-Targeted CAR T-cell Therapy, in Heavily Pretreated Multiple Myeloma: Updated Phase I Study Results

Conference Coverage
Slideset

Updated analysis of results from the first-in-human phase I trial of arlocabtagene autoleucel demonstrated a manageable safety profile and promising efficacy among patients with heavily pretreated relapsed/refractory multiple myeloma.

Released: December 12, 2024

Expiration: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation